Kwan Ting Chow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kwan Ting Chow has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Michael Gale
Department of Immunology, University of Washington, Seattle, USA
5 shared publications - King Hoo Lim
Department of Biomedical Science, City university of Hong Kong
4 shared publications - Andrew L. Kung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
3 shared publications King Hoo Lim
3 shared publications- Mark S. Schlissel
Department of Molecular & Cell Biology, University of California, Berkeley, Berkeley, CA 94720
3 shared publications Meijun Wang
Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong SAR
3 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Elsevier in SSRN Electronic Journal
Host-compatible cardiac fibroblast-derived ECM patches promote myocardial repair after infarction
Cardiac extracellular matrix (ECM) patches provide tissue-specific environments for localized cell delivery after myocardial infarction (MI), but their translation is limited by reliance on xenogeneic tissues or non-cardiac ECM sources. Here, we developed a scalable cardiac fibroblast (CF)-derived ECM patch that combines cardiac-associated matrix cues with improved host compatibility. A matrix-stimulatory cocktail and three-dimensional PLGA mesh culture system enhanced ECM production by multiple matrix-secreting cell types and enabled fabrication of transplantable patches. Transcriptomic and proteomic analyses demonstrated cardiac-associated signatures in human induced pluripotent stem cell-derived CFs and their ECM patches compared with non-cardiac fibroblast controls. In immunocompetent rats, same-strain rat CF-derived ECM patches induced less myocardial macrophage infiltration than xenogeneic human CF-derived patches. Mesenchymal stromal cell-loaded, same-strain CF-derived ECM patches produced sustained functional improvement, increased vascularization and viable myocardium, and reduced fibrosis after MI without systemic immunosuppression. These findings identify host compatibility as an important determinant of ECM patch-mediated cell therapy and establish CF-derived ECM as a promising platform for myocardial repair, with future potential for patient-derived and immune-matched applications.
- 9 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessHost-compatible cardiac fibroblast-derived ECM patches promote myocardial repair after infarction
Cardiac extracellular matrix (ECM) patches provide tissue-specific environments for localized cell delivery after myocardial infarction (MI), but their translation is limited by reliance on xenogeneic tissues or non-cardiac ECM sources. Here, we developed a scalable cardiac fibroblast (CF)-derived ECM patch that combines cardiac-associated matrix cues with improved host compatibility. A matrix-stimulatory cocktail and three-dimensional PLGA mesh culture system enhanced ECM production by multiple matrix-secreting cell types and enabled fabrication of transplantable patches. Transcriptomic and proteomic analyses demonstrated cardiac-associated signatures in human induced pluripotent stem cell-derived CFs and their ECM patches compared with non-cardiac fibroblast controls. In immunocompetent rats, same-strain rat CF-derived ECM patches induced less myocardial macrophage infiltration than xenogeneic human CF-derived patches. Mesenchymal stromal cell-loaded, same-strain CF-derived ECM patches produced sustained functional improvement, increased vascularization and viable myocardium, and reduced fibrosis after MI without systemic immunosuppression. These findings identify host compatibility as an important determinant of ECM patch-mediated cell therapy and establish CF-derived ECM as a promising platform for myocardial repair, with future potential for patient-derived and immune-matched applications.
- Open Access
- 19 May 2026
- Published by SAGE Publications in Journal of Tissue Engineering
- Vol. 17
Cell-free therapy for alopecia via the secretome of hiPSC-derived dermal papilla cells
Alopecia is highly prevalent and debilitating, yet current drugs provide limited, reversible benefit with notable side effects. We established a rapid protocol to generate human induced pluripotent stem cell–derived dermal papilla cells (hiPSC-DPCs) and demonstrated that their conditioned medium (CM) acts as a potent, cell-free hair-regenerative therapy. Transdermal delivery of hiPSC-DPCs or CM accelerated anagen re-entry and hair regrowth in depilated mice, and hiPSC-DPC CM outperformed minoxidil in promoting ex vivo hair-shaft elongation and in vitro proliferation and migration of primary DPCs and keratinocytes. Proteomic and metabolomic profiling revealed enrichment of growth factors, antioxidants, and immunomodulatory metabolites linked to TNF and PI3K–Akt signaling, conferring superior anti-inflammatory and cytoprotective properties relative to primary DPC CM. Moreover, hiPSC-DPC CM mitigated dihydrotestosterone (DHT)-induced pathology by suppressing androgen receptor expression and nuclear translocation. These findings position hiPSC-DPC secretome as a dual-functional, regenerative, and anti-androgenic biologic with translational potential for durable alopecia treatment.
- 19 May 2026
- Published by SAGE Publications in Journal of Tissue Engineering
- Vol. 17
Open AccessCell-free therapy for alopecia via the secretome of hiPSC-derived dermal papilla cells
Alopecia is highly prevalent and debilitating, yet current drugs provide limited, reversible benefit with notable side effects. We established a rapid protocol to generate human induced pluripotent stem cell–derived dermal papilla cells (hiPSC-DPCs) and demonstrated that their conditioned medium (CM) acts as a potent, cell-free hair-regenerative therapy. Transdermal delivery of hiPSC-DPCs or CM accelerated anagen re-entry and hair regrowth in depilated mice, and hiPSC-DPC CM outperformed minoxidil in promoting ex vivo hair-shaft elongation and in vitro proliferation and migration of primary DPCs and keratinocytes. Proteomic and metabolomic profiling revealed enrichment of growth factors, antioxidants, and immunomodulatory metabolites linked to TNF and PI3K–Akt signaling, conferring superior anti-inflammatory and cytoprotective properties relative to primary DPC CM. Moreover, hiPSC-DPC CM mitigated dihydrotestosterone (DHT)-induced pathology by suppressing androgen receptor expression and nuclear translocation. These findings position hiPSC-DPC secretome as a dual-functional, regenerative, and anti-androgenic biologic with translational potential for durable alopecia treatment.
- Open Access
Breast cancer interactions with osteoclasts generate osteoclast-tumor hybrid-like cells through dynamic non-canonical cell fusion and cell-in-cell processes
Macrophages/osteoclasts are highly fusogenic cells that interact closely with bone-metastatic breast cancer cells. These cancer cells adapt to bone microenvironments by undergoing osteomimicry, acquiring bone-like phenotypes. Exploration using human breast cancer-bone metastases dataset revealed that a small population of epithelial breast cancer cells express osteoclast-like and osteomimicry genes at the single-cell level. Cell fusion and cell-in-cell (CIC) processes are two uncommon yet prognostically significant mechanisms in cancer. We showed that co-culture between murine breast cancer cells and osteoclasts yielded a unique osteoclast phenotype through dynamic cell-in-cell (CIC) interactions and fusion-like behaviours between pre-osteoclasts/mature osteoclasts and breast tumor cells, resulting in osteoclast–tumor hybrid-like cells. These tumor cell interactions characterized by membrane retention and nuclear adjacency to host nuclei were consistently observed throughout osteoclast differentiation. Single-cell sequencing analysis and interpretative assays on hybrid-like cells revealed altered extracellular matrix (ECM) modification processes, immunoregulatory, and cancer-associated pathways compared to unfused osteoclasts. Tumor cells co-cultured with osteoclasts expressed hematopoietic and osteoclast-lineage factors more strongly than tumor cells cultured alone with their effects amplified under direct cell-cell contact. The presence of these hybrid-like cells was validated in human breast cancer-bone metastases. We propose that disseminated bone-tropic breast cancer cells were stimulated by osteoclasts to undergo a non-canonical, dynamic osteoclast differentiation and CIC formation to form hybrid-like cells that may facilitate bone metastatic lesions.
Open AccessBreast cancer interactions with osteoclasts generate osteoclast-tumor hybrid-like cells through dynamic non-canonical cell fusion and cell-in-cell processes
Macrophages/osteoclasts are highly fusogenic cells that interact closely with bone-metastatic breast cancer cells. These cancer cells adapt to bone microenvironments by undergoing osteomimicry, acquiring bone-like phenotypes. Exploration using human breast cancer-bone metastases dataset revealed that a small population of epithelial breast cancer cells express osteoclast-like and osteomimicry genes at the single-cell level. Cell fusion and cell-in-cell (CIC) processes are two uncommon yet prognostically significant mechanisms in cancer. We showed that co-culture between murine breast cancer cells and osteoclasts yielded a unique osteoclast phenotype through dynamic cell-in-cell (CIC) interactions and fusion-like behaviours between pre-osteoclasts/mature osteoclasts and breast tumor cells, resulting in osteoclast–tumor hybrid-like cells. These tumor cell interactions characterized by membrane retention and nuclear adjacency to host nuclei were consistently observed throughout osteoclast differentiation. Single-cell sequencing analysis and interpretative assays on hybrid-like cells revealed altered extracellular matrix (ECM) modification processes, immunoregulatory, and cancer-associated pathways compared to unfused osteoclasts. Tumor cells co-cultured with osteoclasts expressed hematopoietic and osteoclast-lineage factors more strongly than tumor cells cultured alone with their effects amplified under direct cell-cell contact. The presence of these hybrid-like cells was validated in human breast cancer-bone metastases. We propose that disseminated bone-tropic breast cancer cells were stimulated by osteoclasts to undergo a non-canonical, dynamic osteoclast differentiation and CIC formation to form hybrid-like cells that may facilitate bone metastatic lesions.
- Open Access
- 28 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (44)
Modulating the microbiome as an approach to anticancer drug development
Recent studies have suggested that the commensal microbiome positively affects cancer prognosis and treatment outcomes. However, only a few strategies for regulating the microbiome composition have been reported. In this study, we identified gold(I) complexes that selectively inhibited nonbeneficial bacterial strains in vitro without affecting commensal Lactobacillus strains. In contrast, clinically used drugs demonstrated comparable effects on both commensal and noncommensal strains. Consistent with the in vitro results, the selected gold(I) complex induced favorable changes in the intratumoral and gastrointestinal microbiomes in vivo. Furthermore, its anticancer efficacy was found to be dependent on the composition of microbiome and correlated with the production of short-chain fatty acid bacterial metabolites. Structure–activity relationship studies have dissected the contribution of each structural component in both the in vivo efficacy and microbiome-modulating properties. Transcriptomic analysis of tumors revealed microbiome-associated gene signaling pathways. These findings provide valuable insights for future research on microbiome-modulating anticancer drugs, presenting potential avenues to optimize cancer treatment outcomes and mitigate side effects such as gastrointestinal dysbiosis. Furthermore, our study provides insights into the involvement of microbiome in the mechanism of action of metal-based chemotherapeutics.
- 28 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (44)
Open AccessModulating the microbiome as an approach to anticancer drug development
Recent studies have suggested that the commensal microbiome positively affects cancer prognosis and treatment outcomes. However, only a few strategies for regulating the microbiome composition have been reported. In this study, we identified gold(I) complexes that selectively inhibited nonbeneficial bacterial strains in vitro without affecting commensal Lactobacillus strains. In contrast, clinically used drugs demonstrated comparable effects on both commensal and noncommensal strains. Consistent with the in vitro results, the selected gold(I) complex induced favorable changes in the intratumoral and gastrointestinal microbiomes in vivo. Furthermore, its anticancer efficacy was found to be dependent on the composition of microbiome and correlated with the production of short-chain fatty acid bacterial metabolites. Structure–activity relationship studies have dissected the contribution of each structural component in both the in vivo efficacy and microbiome-modulating properties. Transcriptomic analysis of tumors revealed microbiome-associated gene signaling pathways. These findings provide valuable insights for future research on microbiome-modulating anticancer drugs, presenting potential avenues to optimize cancer treatment outcomes and mitigate side effects such as gastrointestinal dysbiosis. Furthermore, our study provides insights into the involvement of microbiome in the mechanism of action of metal-based chemotherapeutics.
- Open Access
- 21 May 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-16
Harnessing intracellular bacteria in bladder by intravesical delivery of antibiotics-loaded nanodiamonds to reduce the recurrence of urinary tract infection
Treating urinary tract infections (UTIs) effectively is a difficult task due to the emergence of antibiotic-resistant bacteria and limited antibiotic access to intracellular bacteria within the bladder lining. Numerous studies of the antibiotics-nanodiamonds (NDs) synthesis and their inhibitory effect on bacteria have been performed previously. However, their effectiveness and toxicity in cell-based and animal infection models remain unclear. In this study, we presented the utilization of biopolymer-coated nanodiamonds for the delivery of tetracycline (TET) to the intracellular bacterial communities within the bladder cells using an intravesical delivery approach, aiming to effectively treat UTIs. Compared with antibiotics alone, the TET-loaded ND-based carrier system significantly improved the clearance of intracellular bacteria in the infected cell and animal models. Moreover, the intravesical delivery avoids the potential toxic effects from NDs accumulation in the organs, and minimizes the loss of the drugs during delivery. These results offer a promising strategy to treat chronic infections and prevent the recurrence of urinary tract infections (rUTIs).
- 21 May 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-16
Open AccessHarnessing intracellular bacteria in bladder by intravesical delivery of antibiotics-loaded nanodiamonds to reduce the recurrence of urinary tract infection
Treating urinary tract infections (UTIs) effectively is a difficult task due to the emergence of antibiotic-resistant bacteria and limited antibiotic access to intracellular bacteria within the bladder lining. Numerous studies of the antibiotics-nanodiamonds (NDs) synthesis and their inhibitory effect on bacteria have been performed previously. However, their effectiveness and toxicity in cell-based and animal infection models remain unclear. In this study, we presented the utilization of biopolymer-coated nanodiamonds for the delivery of tetracycline (TET) to the intracellular bacterial communities within the bladder cells using an intravesical delivery approach, aiming to effectively treat UTIs. Compared with antibiotics alone, the TET-loaded ND-based carrier system significantly improved the clearance of intracellular bacteria in the infected cell and animal models. Moreover, the intravesical delivery avoids the potential toxic effects from NDs accumulation in the organs, and minimizes the loss of the drugs during delivery. These results offer a promising strategy to treat chronic infections and prevent the recurrence of urinary tract infections (rUTIs).
- Open Access
- 26 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0320441
New insights on Galectin-9 expression in cancer prognosis: An updated systemic review and meta-analysis
Galectin-9 (Gal-9) has gained increasing attention in recent years in the field of cancer immunology. Its interactions with various immune cell types in the tumor microenvironment influence tumor progression, making it a novel target for immunotherapy. Despite its potential as a therapeutic target, the prognostic significance of Gal-9 in tumor cells remains unclear. Conflicting data exists on its expression levels and outcomes, prompting a comprehensive review and meta-analysis to elucidate its independent prognostic role across different cancer types. This study aims to examine the varying effects of Gal-9 expression across various cancer subtypes, providing insights into its potential as a prognostic marker and highlighting its significance in the realm of cancer treatment. To assess the prognostic significance of Gal-9 expression in cancer, we conducted a comprehensive database search across PubMed, Embase, and Web of Science, incorporating studies published until December 2024, regardless of language. Using pooled hazard ratios (HRs) with 95% confidence intervals (CIs), we evaluated the role of Gal-9 expression in predicting cancer outcomes across various cancer types. Our analysis encompassed 29 studies with a total of 4,720 patients to investigate the prognostic significance of Gal-9 expression across different cancer types. The results demonstrated that elevated Gal-9 expression was significantly associated with improved overall survival (OS) in solid tumors, with a pooled hazard ratio of 0.75 (95% CI: 0.63-0.90, p = 0.002). No statistically significant correlation was observed between Gal-9 expression and cancer recurrence (HR = 0.88, 95% CI: 0.65–1.19, p = 0.42). Conversely, in hematological cancers, high Gal-9 expression correlated with more rapid disease progression, as reflected by progression-free survival (PFS) or time to treatment (TTT) (HR = 2.29, 95% CI: 1.26–4.16, p = 0.007). The subgroup analyses further revealed that higher Gal-9 expression was associated with OS in gastrointestinal and urological cancers and was linked to disease-free survival (DFS) and recurrence-free survival (RFS) in hepatobiliary and urological cancers. Our research has uncovered that Gal-9 serves as a promising prognostic indicator for solid tumors, offering valuable insights into patient outcomes. High levels of Gal-9 expression within gastrointestinal, hepatobiliary, and urological cancers have been linked to better prognoses, while its presence in hematological cancers is associated with poorer outcomes. These contrasting findings emphasize the importance of interpreting biomarkers with careful consideration to the specific context. Moreover, our study sheds light on the diverse physiological roles of intracellular and secreted Gal-9, highlighting the intricate ways in which this protein influences cancer progression.
- 26 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0320441
Open AccessNew insights on Galectin-9 expression in cancer prognosis: An updated systemic review and meta-analysis
Galectin-9 (Gal-9) has gained increasing attention in recent years in the field of cancer immunology. Its interactions with various immune cell types in the tumor microenvironment influence tumor progression, making it a novel target for immunotherapy. Despite its potential as a therapeutic target, the prognostic significance of Gal-9 in tumor cells remains unclear. Conflicting data exists on its expression levels and outcomes, prompting a comprehensive review and meta-analysis to elucidate its independent prognostic role across different cancer types. This study aims to examine the varying effects of Gal-9 expression across various cancer subtypes, providing insights into its potential as a prognostic marker and highlighting its significance in the realm of cancer treatment. To assess the prognostic significance of Gal-9 expression in cancer, we conducted a comprehensive database search across PubMed, Embase, and Web of Science, incorporating studies published until December 2024, regardless of language. Using pooled hazard ratios (HRs) with 95% confidence intervals (CIs), we evaluated the role of Gal-9 expression in predicting cancer outcomes across various cancer types. Our analysis encompassed 29 studies with a total of 4,720 patients to investigate the prognostic significance of Gal-9 expression across different cancer types. The results demonstrated that elevated Gal-9 expression was significantly associated with improved overall survival (OS) in solid tumors, with a pooled hazard ratio of 0.75 (95% CI: 0.63-0.90, p = 0.002). No statistically significant correlation was observed between Gal-9 expression and cancer recurrence (HR = 0.88, 95% CI: 0.65–1.19, p = 0.42). Conversely, in hematological cancers, high Gal-9 expression correlated with more rapid disease progression, as reflected by progression-free survival (PFS) or time to treatment (TTT) (HR = 2.29, 95% CI: 1.26–4.16, p = 0.007). The subgroup analyses further revealed that higher Gal-9 expression was associated with OS in gastrointestinal and urological cancers and was linked to disease-free survival (DFS) and recurrence-free survival (RFS) in hepatobiliary and urological cancers. Our research has uncovered that Gal-9 serves as a promising prognostic indicator for solid tumors, offering valuable insights into patient outcomes. High levels of Gal-9 expression within gastrointestinal, hepatobiliary, and urological cancers have been linked to better prognoses, while its presence in hematological cancers is associated with poorer outcomes. These contrasting findings emphasize the importance of interpreting biomarkers with careful consideration to the specific context. Moreover, our study sheds light on the diverse physiological roles of intracellular and secreted Gal-9, highlighting the intricate ways in which this protein influences cancer progression.
- Open Access
- 22 August 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 12
Cell chirality reversal through tilted balance between polymerization of radial fibers and clockwise-swirling of transverse arcs
Cell chirality is an intrinsic property shown as biased cell rotation or orientation. Although the right-handed double helix of actin is known important, how a single form of molecular handedness manifests diverse forms of cell chirality remains unclear. Here, we found that the cell nucleus rotated with a clockwise (CW) bias in a small projected area, but this rotation reversed to an anticlockwise (ACW) bias as cell spreading increased. Actin analysis suggested that radial fiber polymerization accounts for the ACW bias. Alterations in transverse arc components (myosin II, mDia2, and tropomyosin 4) revealed that the CW bias is driven by the retrograde flow, originating from the tethered gliding motion of myosin II in the contractile structure of transverse arcs. Thus, an imbalance between radial fibers and transverse arcs results in cell chirality reversal. The findings elucidate the mechanisms underlying cell chirality reversal, providing a new perspective on mechanobiology.
- 22 August 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 12
Open AccessCell chirality reversal through tilted balance between polymerization of radial fibers and clockwise-swirling of transverse arcs
Cell chirality is an intrinsic property shown as biased cell rotation or orientation. Although the right-handed double helix of actin is known important, how a single form of molecular handedness manifests diverse forms of cell chirality remains unclear. Here, we found that the cell nucleus rotated with a clockwise (CW) bias in a small projected area, but this rotation reversed to an anticlockwise (ACW) bias as cell spreading increased. Actin analysis suggested that radial fiber polymerization accounts for the ACW bias. Alterations in transverse arc components (myosin II, mDia2, and tropomyosin 4) revealed that the CW bias is driven by the retrograde flow, originating from the tethered gliding motion of myosin II in the contractile structure of transverse arcs. Thus, an imbalance between radial fibers and transverse arcs results in cell chirality reversal. The findings elucidate the mechanisms underlying cell chirality reversal, providing a new perspective on mechanobiology.
- Open Access
- 9 July 2024
- Published by Springer Nature in Research Square
Cell chirality reversal through tilted balance betweenpolymerization of radial bers and clockwise-swirling of transverse arcs
Cell chirality is an intrinsic property shown as biased cell rotation or orientation. While the righthanded helix of actin is known essential, it is intriguing of how single form of molecular handedness can be manifested into diverse and even mirrored forms of cell chirality. Here, we found that cell nucleus rotates with clockwise (CW) bias with smaller projected area but reverses to anticlockwise (ACW) bias when cell spreading increases. Actin analysis suggests that polymerization of righthanded radial fibers accounts for the ACW bias, while the CW bias is driven by the retrograde flow of CW-swirling transverse arc, which originates from tethered myosin II that simultaneously connect radial fibers and transverse arc. Thus, by tilting the balance between these two classes of actin fibers via cell spreading area or the main factors of actin, i.e., myosin II, α-actinin-1, Tpm4, and mDia2, the single form of actin helix can be unfolded into cell chirality with opposite bias. This finding suggests a mechanistic insight of cell chirality reversal, providing new perspective in mechanobiology and tissue formation.
- 9 July 2024
- Published by Springer Nature in Research Square
Open AccessCell chirality reversal through tilted balance betweenpolymerization of radial bers and clockwise-swirling of transverse arcs
Cell chirality is an intrinsic property shown as biased cell rotation or orientation. While the righthanded helix of actin is known essential, it is intriguing of how single form of molecular handedness can be manifested into diverse and even mirrored forms of cell chirality. Here, we found that cell nucleus rotates with clockwise (CW) bias with smaller projected area but reverses to anticlockwise (ACW) bias when cell spreading increases. Actin analysis suggests that polymerization of righthanded radial fibers accounts for the ACW bias, while the CW bias is driven by the retrograde flow of CW-swirling transverse arc, which originates from tethered myosin II that simultaneously connect radial fibers and transverse arc. Thus, by tilting the balance between these two classes of actin fibers via cell spreading area or the main factors of actin, i.e., myosin II, α-actinin-1, Tpm4, and mDia2, the single form of actin helix can be unfolded into cell chirality with opposite bias. This finding suggests a mechanistic insight of cell chirality reversal, providing new perspective in mechanobiology and tissue formation.
- Open Access
- 8 June 2024
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 120 (14) , 1737-1751
Daily oral administration of probiotics engineered to constantly secrete short-chain fatty acids effectively prevents myocardial injury from subsequent ischaemic heart disease
Given the extremely limited regeneration potential of the heart, one of the most effective strategies to reduce the prevalence and mortality of coronary artery disease is prevention. Short-chain fatty acids (SCFAs), which are by-products of beneficial probiotics, have been reported to possess cardioprotective effects. Despite their beneficial roles, delivering SCFAs and maintaining their effective concentration in plasma present major challenges. Therefore, in the present study, we aimed to devise a strategy to prevent coronary heart disease effectively by using engineered probiotics to continuously release SCFAs in vivo. We engineered a novel probiotic cocktail, EcN_TL, from the commercially available Escherichia coli Nissle 1917 strain to continuously secrete SCFAs by introducing the propionate and butyrate biosynthetic pathways. Oral administration of EcN_TL enhanced and maintained an effective concentration of SCFAs in the plasma. As a preventative strategy, we observed that daily intake of EcN_TL for 14 days prior to ischemia-reperfusion injury significantly reduced myocardial injury and improved cardiac performance compared to EcN administration. We uncovered that EcN_TL’s protective mechanisms included reducing neutrophil infiltration into the infarct site and promoting the polarization of wound-healing macrophages. We further revealed that SCFAs at plasma concentration protected cardiomyocytes from inflammation by suppressing the NF-κB activation pathway. These data provide strong evidence to support the use of SCFA-secreting probiotics to prevent coronary heart disease. Since SCFAs also play a key role in other metabolic diseases, EcN_TL can potentially be used to treat a variety of other diseases.
- 8 June 2024
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 120 (14) , 1737-1751
Open AccessDaily oral administration of probiotics engineered to constantly secrete short-chain fatty acids effectively prevents myocardial injury from subsequent ischaemic heart disease
Given the extremely limited regeneration potential of the heart, one of the most effective strategies to reduce the prevalence and mortality of coronary artery disease is prevention. Short-chain fatty acids (SCFAs), which are by-products of beneficial probiotics, have been reported to possess cardioprotective effects. Despite their beneficial roles, delivering SCFAs and maintaining their effective concentration in plasma present major challenges. Therefore, in the present study, we aimed to devise a strategy to prevent coronary heart disease effectively by using engineered probiotics to continuously release SCFAs in vivo. We engineered a novel probiotic cocktail, EcN_TL, from the commercially available Escherichia coli Nissle 1917 strain to continuously secrete SCFAs by introducing the propionate and butyrate biosynthetic pathways. Oral administration of EcN_TL enhanced and maintained an effective concentration of SCFAs in the plasma. As a preventative strategy, we observed that daily intake of EcN_TL for 14 days prior to ischemia-reperfusion injury significantly reduced myocardial injury and improved cardiac performance compared to EcN administration. We uncovered that EcN_TL’s protective mechanisms included reducing neutrophil infiltration into the infarct site and promoting the polarization of wound-healing macrophages. We further revealed that SCFAs at plasma concentration protected cardiomyocytes from inflammation by suppressing the NF-κB activation pathway. These data provide strong evidence to support the use of SCFA-secreting probiotics to prevent coronary heart disease. Since SCFAs also play a key role in other metabolic diseases, EcN_TL can potentially be used to treat a variety of other diseases.